Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on...
Mental Health
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on...
Standout Digital Health and Medical Technology Innovators Honored in 2024 MedTech Breakthrough Awards Program
International Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and CompaniesLOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) --...
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to...
Greene Concepts and Tocca Life Holdings Join Forces Within $4.5 Trillion U.S. Healthcare Industry to Increase Vitality Nationwide
Marion, North Carolina--(Newsfile Corp. - May 7, 2024) - Greene Concepts Inc. (OTC PINK: INKW) and Tocca Life Holdings, Inc....
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
U.S. Medical Kiosks Market Insights Report 2024-2029, with Data on 39 Key Vendors Including Fabcon, Meridian, Verifone, Xiphias Software Technologies and Redyref – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "U.S. Medical Kiosks Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The U.S. Medical...
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for...
Compass Pathways to announce first quarter financial results on May 8, 2024
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access...
Anxiety Canada Breaking Barriers to Mental Health Support
Collaboration with TELUS Health expands access to therapy for people in Canada through exceptional personalized counsellingTORONTO, ON / ACCESSWIRE /...
Safe Supply Streaming: Pioneering Solutions in the Addiction Crisis through Strategic Partnerships and Innovation
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe Supply"...
Osmind Announces Collaboration with the American Psychiatric Association to Advance Quality Psychiatric Care and Accelerate Research
This innovative collaboration will help improve adoption of measurement-based care and precision psychiatry to enhance diagnostic and treatment practicesSAN FRANCISCO--(BUSINESS...
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
Trial planning and execution to proceed as planned WASHINGTON, May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP;...
VitalHub Announces Q1 2024 Conference Call Date
TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") (TSX: VHI) (OTCQX:VHIBF) is pleased to announce...
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
VANCOUVER, BC / ACCESSWIRE / May 2, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage...
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearanceMALVERN, Pa., May...
MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
VANCOUVER, BC / ACCESSWIRE / May 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to...
Reimagine Care Unveils Expansion of Distinguished Clinical Advisory Board to Advance Virtual-first Cancer Care Innovation
NASHVILLE, Tenn.--(BUSINESS WIRE)--Reimagine Care, the nation’s leading provider of virtual-first cancer care, proudly announces the expansion of its esteemed Clinical...
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials...
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency...